We’re in the middle of a mental health crisis. By 2030, the global economic burden of mental health issues will be 12 times larger than that of cancer. Meanwhile, 30% of patients who try two traditional treatments for depression (like SSRIs) relapse and see no lasting relief. Thankfully, 2022 has been a landmark year for mental health research and care.

‍

Telehealth has grown to account for 36% of all outpatient mental health visits, enabling psychiatrists to help more patients. Meanwhile, innovative treatments for depression like ketamine and TMS are finally breaking through to mainstream awareness for their proven benefits. However, regulatory and cost barriers restrict access to these life-saving treatments for millions of people who can’t afford to pay out of pocket.

‍

At Osmind, our mission is to empower clinicians and researchers to bring innovative mental health treatments to patients who need them most. We want to promote worldwide healing and overcome this global crisis, and we’re thankful to everyone who joins us.

‍

Here's a look back at some of the biggest advancements we’ve made in 2022.

‍

Our clinicians spent less time navigating software and more time expanding their patient care

‍

A 2022 study found that full-time physicians spend 3.5 to 6 hours per day inside electronic health records (EHRs). Most of this time is spent on clerical and administrative tasks, such as repetitive logins and inbox management, creating a significant time burden while consuming valuable time that could be spent on patient care.

‍

To address this, we added several features to help psychiatrists and mental health clinicians streamline their workflows and keep patients engaged. Integrated payments let clinicians focus on care and expand access by generating and submitting invoices and superbills directly through the Osmind app. A Zoom integration powers virtual visits, which help clinicians expand services to patients with moderate to severe mental health conditions who may have difficulty coming in person for an appointment. Finally, a library of over 60 templates saves clinicians valuable documentation time.

‍

Osmind clinicians collected over 2 million patient rating scales to improve clinical care

‍

Clinicians on the Osmind platform have now collected over two million patient rating scales via response to automated surveys sent through the Osmind platform. Rating scales are standardized measures of a patient’s progress and contribute to measurement-based care (MBC).

‍

Research shows that MBC can help increase the therapeutic effect size, detect symptom deterioration faster, improve patient adherence, and give patients a deeper sense of agency over their treatment journey. Moreover, visualizing data inside Osmind helps establish a strong bond between patient and provider. Patients become more aware of their own progress and clinicians recognize early signs of relapse or promising signs of improvement.

‍

We advanced breakthrough mental health research

‍

Our own VP of medical affairs, Dr. Alison McInnes, led the publication of the largest retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. This study is known as Osmind Real-World Ketamine Analyses (ORKA).

‍

The goal of ORKA is to understand the efficacy and safety of ketamine therapy as it is practiced in the community, versus the more limited scope of clinical trials. Clinical trials can only assess a specific combination of controlled parameters. Additionally, it’s unclear how patients enrolled in prospective, randomized trials (usually in academic medical centers) compare to those seeking care in private practice.

‍

In the real world, a variety of treatment regimens and patient characteristics intersect. As the majority of patients receiving ketamine are treated in community practices, it is crucial to assess outcomes in these settings. Such real-world evidence is critical to establish the safety and efficacy of new treatments for patients and obtaining the necessary support of payers to ensure broad access to care.

‍

Our community of leading-edge mental health clinicians continues to grow and thrive

‍

Clinicians often feel like they have to navigate the murky waters of mental health care alone—especially those either in private practice or just getting started. Staying informed on the latest research and finding a sense of community is not easy, and current solutions like Facebook groups don’t fill the gap. That’s why we launched the Osmind Practice Community, and have since grown it to hundreds of members and hosted nearly 30 virtual events.

‍

Clinicians and practice managers alike can expand their network, discuss clinical quandaries, share referrals, explore a library of practice management tips, and collaborate on research projects.

‍

We raised $40M in financing to address the need for innovative mental health care

‍

Osmind closed our $40 million series B fundraising round, led by DFJ Growth.

Justin Kao of DFJ Growth, along with Brent Saunders, former CEO & Chairman of Allergan, also joined Osmind’s Board of Directors.

‍

Combined, they bring decades of healthcare and biopharmaceutical experience, and their inclusion is invaluable to helping us achieve our mission. The funds will help us continue to develop and scale the Osmind EHR platform to meet the needs of innovative mental health clinicians.

‍

We reimagined the Osmind brand to reflect the odyssey ahead

‍

The patient journey through depression is hardly ever a straight line. As humans, we carry the most complex “operating system” between our ears. In the face of an increasingly stressful world, mental healthcare companies aiming to challenge the status quo need to balance timeless wisdom with fresh approaches.

‍

Osmind is named for the pioneering psychiatrist and researcher Dr. Humphry Osmond and our vision to be the “Operating System for the mind.” To evolve our unique name, we updated our logo with precise, elegant custom typography with a strong dose of symmetry. The color gradient across the word “Osmind” goes from dark to light, representing the mental health journey. The color transition is incremental, not stepwise, reflecting the difficult process of treating and overcoming refractory and serious psychiatric conditions.

‍

We published our first Public Benefit Corporation report

‍

Osmind is focused on improving access to mental health care, reducing stigma around mental illness, and supporting mental health research and advocacy. That’s why we’re proud to be a Public Benefit Corporation (PBC), and publish our first PBC report this year. A PBC is a type of corporation that must consider its decisions' impact on society, not just on its shareholders. This means that, in addition to pursuing profit, PBCs must also consider the broader social and environmental impact of their actions.

‍

We gained a new scientific advisory board member to help us integrate the latest mental health research

‍

Dr. Carolyn Rodriguez, MD, PhD, Associate Dean for Academic Affairs at Stanford University School of Medicine, and Associate Chair for Inclusion and Diversity in the Department of Psychiatry and Behavioral Sciences at Stanford University joined our scientific advisory board. As the Director of the Translational Therapeutics Lab and Associate Professor in the Department of Psychiatry and Behavioral Sciences, Dr. Rodriguez leads studies investigating the brain basis of severe mental disorders.

‍

Dr. Rodriguez joins Dr. Maurizio Fava, Dr. Robin Carhart-Harris, Dr. Charles DeBattista, and Dr. Boris Heifets on Osmind’s Scientific Advisory Board. We’re humbled to join forces with leading researchers and thought leaders in psychiatry, neuropsychiatry, and anesthesiology.

‍

We’re grateful to everyone who made this a landmark year!

‍

Mental health is one of the most impactful crises of our lifetimes, and it takes a village to disrupt the status quo.

‍

Osmind is grateful to its clinician community and our collective work to expand access to evidence-based mental health treatments to patients who need them the most.

We look forward to working tirelessly in 2023 to help mental health clinicians reclaim their time, generate real-world evidence, and expand patient care.